113 related articles for article (PubMed ID: 38319049)
1. Structure-based evaluation of the envelope domain III-nonstructural protein 1 (EDIII-NS1) fusion as a dengue virus vaccine candidate.
Shoushtari M; Rismani E; Salehi-Vaziri M; Azadmanesh K
J Biomol Struct Dyn; 2024 Feb; ():1-19. PubMed ID: 38319049
[TBL] [Abstract][Full Text] [Related]
2. Designing vaccine candidates against dengue virus by in silico studies on structural and nonstructural domains.
Shoushtari M; Mafakher L; Rahmati S; Salehi-Vaziri M; Arashkia A; Roohvand F; Teimoori-Toolabi L; Azadmanesh K
Mol Cell Probes; 2022 Jun; 63():101818. PubMed ID: 35461964
[TBL] [Abstract][Full Text] [Related]
3. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
[TBL] [Abstract][Full Text] [Related]
4. Immunoinformatics design of a novel epitope-based vaccine candidate against dengue virus.
Fadaka AO; Sibuyi NRS; Martin DR; Goboza M; Klein A; Madiehe AM; Meyer M
Sci Rep; 2021 Oct; 11(1):19707. PubMed ID: 34611250
[TBL] [Abstract][Full Text] [Related]
5. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY
J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440
[TBL] [Abstract][Full Text] [Related]
6. A novel chimeric dengue vaccine candidate composed of consensus envelope protein domain III fused to C-terminal-modified NS1 protein.
Huang HJ; Yang M; Chen HW; Wang S; Chang CP; Ho TS; Kao YS; Tien SM; Lin HH; Chang PC; Lai YC; Hsiao YP; Liu YL; Chao CH; Anderson R; Yeh TM; Lin YS; Wan SW
Vaccine; 2022 Apr; 40(15):2299-2310. PubMed ID: 35287985
[TBL] [Abstract][Full Text] [Related]
7. Development of a tetravalent subunit vaccine against dengue virus through a vaccinomics approach.
Basheer A; Jamal SB; Alzahrani B; Faheem M
Front Immunol; 2023; 14():1273838. PubMed ID: 38045699
[TBL] [Abstract][Full Text] [Related]
8. Addition of Partial Envelope Domain II into Envelope Domain III of Dengue Virus Antigen Potentiates the Induction of Virus-Neutralizing Antibodies and Induces Protective Immunity.
Park J; Lee HY; Khai LT; Thuy NTT; Mai LQ; Jang YS
Vaccines (Basel); 2020 Feb; 8(1):. PubMed ID: 32075300
[TBL] [Abstract][Full Text] [Related]
9. Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4
Zaneti AB; Yamamoto MM; Sulczewski FB; Almeida BDS; Souza HFS; Ferreira NS; Maeda DLNF; Sales NS; Rosa DS; Ferreira LCS; Boscardin SB
Front Immunol; 2019; 10():59. PubMed ID: 30761131
[TBL] [Abstract][Full Text] [Related]
10. Immune profile and responses of a novel dengue DNA vaccine encoding an EDIII-NS1 consensus design based on Indo-African sequences.
Sankaradoss A; Jagtap S; Nazir J; Moula SE; Modak A; Fialho J; Iyer M; Shastri JS; Dias M; Gadepalli R; Aggarwal A; Vedpathak M; Agrawal S; Pandit A; Nisheetha A; Kumar A; Bordoloi M; Shafi M; Shelar B; Balachandra SS; Damodar T; Masika MM; Mwaura P; Anzala O; Muthumani K; Sowdhamini R; Medigeshi GR; Roy R; Pattabiraman C; Krishna S; Sreekumar E
Mol Ther; 2022 May; 30(5):2058-2077. PubMed ID: 34999210
[TBL] [Abstract][Full Text] [Related]
11. Recombinant Protein Mimicking the Antigenic Structure of the Viral Surface Envelope Protein Reinforces Induction of an Antigen-Specific and Virus-Neutralizing Immune Response Against Dengue Virus.
Kim J; Lim TY; Park J; Jang YS
J Microbiol; 2023 Jan; 61(1):131-143. PubMed ID: 36723792
[TBL] [Abstract][Full Text] [Related]
12. Exploring dengue proteome to design an effective epitope-based vaccine against dengue virus.
Sabetian S; Nezafat N; Dorosti H; Zarei M; Ghasemi Y
J Biomol Struct Dyn; 2019 Jul; 37(10):2546-2563. PubMed ID: 30035699
[TBL] [Abstract][Full Text] [Related]
13. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
[TBL] [Abstract][Full Text] [Related]
14. In silico construction of a multiepitope Zika virus vaccine using immunoinformatics tools.
Antonelli ACB; Almeida VP; de Castro FOF; Silva JM; Pfrimer IAH; Cunha-Neto E; Maranhão AQ; Brígido MM; Resende RO; Bocca AL; Fonseca SG
Sci Rep; 2022 Jan; 12(1):53. PubMed ID: 34997041
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of cell-surface displayed synthetic consensus dengue EDIII cells as a potent oral vaccine candidate.
Bal J; Jung HY; Nguyen LN; Park J; Jang YS; Kim DH
Microb Cell Fact; 2018 Sep; 17(1):146. PubMed ID: 30217208
[TBL] [Abstract][Full Text] [Related]
16. A bivalent form of nanoparticle-based dengue vaccine stimulated responses that potently eliminate both DENV-2 particles and DENV-2-infected cells.
Seesen M; Jearanaiwitayakul T; Limthongkul J; Midoeng P; Sunintaboon P; Ubol S
Vaccine; 2023 Feb; 41(9):1638-1648. PubMed ID: 36740559
[TBL] [Abstract][Full Text] [Related]
17. Blueprint of epitope-based multivalent and multipathogenic vaccines: targeted against the dengue and zika viruses.
Sarkar B; Ullah MA; Araf Y; Das S; Hosen MJ
J Biomol Struct Dyn; 2021 Nov; 39(18):6882-6902. PubMed ID: 32772811
[TBL] [Abstract][Full Text] [Related]
18. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
[TBL] [Abstract][Full Text] [Related]
19. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.
Galula JU; Shen WF; Chuang ST; Chang GJ; Chao DY
J Virol; 2014 Sep; 88(18):10813-30. PubMed ID: 25008922
[TBL] [Abstract][Full Text] [Related]
20. Rational design of multi-epitope-based vaccine by exploring all dengue virus serotypes proteome: an immunoinformatic approach.
Alsaiari AA; Hakami MA; Alotaibi BS; Alkhalil SS; Hazazi A; Alkhorayef N; Jalal K; Yasmin F
Immunol Res; 2024 Apr; 72(2):242-259. PubMed ID: 37880483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
